Pharmacokinetic consultation program in a pediatric asthma clinic
J H Botha1, I Tyrannes, R Miller
1Department of Pharmacology, University of Natal (UN), Durban, South Africa.
American Journal of Hospital Pharmacy
|August 1, 1992
Summary
A clinical pharmacokinetic consultation program for theophylline significantly improved asthma outcomes in pediatric patients. This involved pharmacist-led medication counseling and dosage adjustments, leading to better symptom control and fewer hospital visits.
Area of Science:
- Pediatric Pulmonology
- Clinical Pharmacy
- Pharmacokinetics
Background:
- Asthma management in children often requires careful theophylline dosage adjustments.
- Clinical pharmacokinetic consultation programs can optimize medication therapy.
Purpose of the Study:
- To evaluate the impact of a clinical pharmacokinetic consultation program for theophylline on pediatric asthma outcomes.
- To assess improvements in clinical symptoms, lung function, and healthcare utilization.
Main Methods:
- A prospective study involving pediatric asthma patients receiving theophylline.
- Pharmacist-led data collection, parent counseling, and dosage adjustments based on pharmacokinetic principles.
- Comparison of patient outcomes at baseline, 5-6 months, and 11-12 months post-program initiation.
Main Results:
- Significant improvements observed in wheezing, exercise tolerance, and nocturnal coughing.
- Enhanced forced expiratory volume in one second and a reduction in hospital visits for asthma exacerbations.
- Increased daily weight-adjusted theophylline dosage indicating optimized therapy.
Conclusions:
- Clinical pharmacokinetic consultation and medication counseling for theophylline therapy in pediatric asthma patients lead to improved clinical outcomes.
- Pharmacist involvement in medication management can enhance patient care and reduce healthcare resource utilization.
Related Concept Videos
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...